The 30-day data presented on the self-expanding CENTERA valve from Edwards Lifesciences Corp (NYSE:EW) are said to have been positive. The transcatheter heart valve, which was used on 203 patients during its clinical trials proved its worth in high-risk open-heart surgeries. The device scored a 99% survival rating with only a 2.5% disabling stroke rate.
Additional observations indicated that the self-expanding valve did not cause paravalvular leaks. Patients who were enrolled into the CENTERA-EU Trial were put in 23 centers across Europe, Australia, and New Zealand
The valve offers several other features
There is a lot to write home about the positive outcome of Edwards CENTERA valve. Nonetheless, it can be concluded that this is just the beginning of the unique features that the device has. For example, it is packaged with a pre-attachment, which facilitates simple and rapid device preparation.
An additional feature points at its repositionable and retrievable ability and it can be delivered through a low-profile 14-French delivery system. The M.D of Clinique Pasteur in Toulouse, France, Didier Tchétché says, “In addition to excellent patient outcomes, the valve also offers several unique features and an innovative tissue design, all of which simplify the procedure for clinicians.”
A sneak peek into Edwards Lifesciences
The Edwards CENTERA valve is not available commercially given that it is still an investigational device. However, there is optimism of an approval of its CE Mark in the fourth quarter of this year. The Irvine, Calif-based global leader in patient-focused medical innovations has been upping its game in helping patients.
Edwards’ primary focus has been on structural heart disease, critical care, and surgical monitoring. It has enlisted the collaboration of some of the world’s leading clinicians and researchers in the creation of innovative solutions that will help in addressing the unmet healthcare needs.
The company has been at the forefront in improving and enhancing people’s lives and it carries Zack’s ranking of position 2. Meanwhile, Edwards’ stock was trading at $111.84 a fall of $1.81 or 1.59%.